*Actual product packaging may differ from the image shown.
Tirzepatide (Injectable)
Depending on the dose prescribed
$149.00–$458.00
Shop All Treatments
Tirzepatide: Weekly Injection That Activates Two Metabolic Pathways at Once
The dual-action GLP-1 and GIP receptor agonist behind the most significant weight loss outcomes in clinical trials to date.
Tirzepatide is a once-weekly injection that targets two of your body’s metabolic hormones at the same time, GLP-1 and GIP. Most people describe it as feeling full sooner, losing food cravings, and seeing weight come off more consistently than with single-hormone GLP-1 medications. It’s the same active molecule found in Mounjaro and Zepbound, dispensed by licensed US compounding pharmacies under the supervision of your prescribing physician.
Physician-prescribed · Compounded by licensed US pharmacies · Personalized titration · Ongoing care team support
Tirzepatide (Dual GIP and GLP-1 Receptor Agonist): Tirzepatide is a synthetic peptide that activates both the GLP-1 and GIP receptors. GLP-1 reduces appetite, slows stomach emptying, and steadies blood sugar. GIP appears to enhance insulin sensitivity and may play a role in fat metabolism. Hitting both pathways together produces larger and more consistent weight loss than activating GLP-1 alone. Your dose is increased gradually over several months, the same way every GLP-1 family medication is started.
Best for: Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition, who want the strongest available pharmacologic option for sustained weight loss. Particularly well-suited for people who have tried single-pathway GLP-1 medications and want a more aggressive metabolic approach.
Not recommended for: People with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome, those with a history of pancreatitis, anyone pregnant or breastfeeding, those with severe gastrointestinal disease, and anyone already taking another GLP-1 medication.
The most common side effects are similar to the GLP-1 class: nausea, diarrhea, vomiting, constipation, and stomach discomfort. These are usually most pronounced early in treatment and during dose increases, then improve as your body adjusts. Rare but serious risks include pancreatitis, gallbladder disease, kidney problems related to dehydration, and (based on animal data) a theoretical risk of medullary thyroid tumors that has not been confirmed in humans. Tirzepatide carries a boxed warning for this risk.
¹ Up to 22.5% average body weight loss at the highest dose Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1 trial). New England Journal of Medicine, 2022;387(3):205-216. → NEJM · PubMed
² 63% of patients lost at least 20% of body weight (15 mg) Jastreboff AM, et al. SURMOUNT-1 (same source as ¹). (63% of the 15 mg group achieved ≥20% weight loss vs 1.3% placebo.) → NEJM · PubMed
³ 96% lost at least 5% of body weight (10 to 15 mg) Jastreboff AM, et al. SURMOUNT-1 (same source as ¹). (96% of the 10 mg and 15 mg groups achieved ≥5% weight loss vs 28% placebo; 89% at 5 mg.) → NEJM · PubMed
Mechanism reference (not a numbered efficacy claim): Min T, Bain SC. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist. Diabetes Therapy, 2021;12(1):143-157. → PubMed
How it Works With EHRX
The entire process is online. No waiting rooms. Just straightforward, medically guided care.
Step 1
Choose your treatment and complete checkout
You'll receive a confirmation email with next steps.
Step 2
Complete a brief medical consultation
Check your email for a link to a short intake form and link to a virtual consult with a licensed physician.
Step 3
A licensed provider reviews your consultation
If approved, your prescription is written and sent to the pharmacy. If not, you receive a full refund.
Step 4
Your pharmacy ships within 3–5 business days
Your medication is shipped directly to your door in temperature-controlled packaging.
What to know before you start.
Tirzepatide (Injectable) is a compounded medication prepared by a licensed pharmacy for individual patient use.
It has not been reviewed by the FDA for safety or efficacy, and is prescribed based on the clinical judgment of a qualified healthcare provider. Compounded drugs are permitted to be prescribed but are not FDA-approved for safety and efficacy.
Clinical Evidence
In the SURMOUNT-1 trial, a 72-week study of 2,539 adults with obesity, participants taking weekly tirzepatide at the highest dose (15 mg) lost an average of 22.5% of their body weight compared with 2.4% in the placebo group. (Source: Jastreboff et al., New England Journal of Medicine, 2022)
Frequently Asked Questions
We aim to provide absolute clarity regarding your biological data and personalized wellness protocols.
Semaglutide acts on one hormone receptor (GLP-1). Tirzepatide acts on two (GLP-1 and GIP). In head-to-head studies and indirect comparisons, tirzepatide produces larger weight loss on average.
Reduced appetite usually begins within the first one to two weeks. Visible weight loss starts by week 4, with continued progress over months.
Once weekly subcutaneous injection in your abdomen, thigh, or upper arm.
Most patients qualify at BMI 30 or higher, or 27 or higher with a weight-related health condition.
A baseline metabolic panel is recommended in most cases.
You won’t be charged for the medication. Your provider will explain why and suggest alternatives.
Compounded versions are typically paid out of pocket. Brand-name Zepbound may be covered depending on your plan.
Yes, at any time before your next shipment, with no long-term commitment.
Monthly during titration, then on a recurring cadence as you stabilize.
Most digestive symptoms improve within a few weeks or with a slower titration. Contact your care team for anything persistent.
Weight regain is common after stopping. Your provider will discuss long-term protocol options.
The next generation
of weight management.
Dual-incretin metabolic support — personalized to you.
